International Journal of Radiation Oncology*Biology*Physics
Clinical investigationPreliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy☆
Introduction
Radiation therapy (RT) is commonly used in the treatment of gynecologic tumors, notably cervical and endometrial cancer. Whereas select patients receive intracavitary brachytherapy (ICB) alone 1, 2, most receive whole pelvic RT (WPRT) alone 3, 4 or combined with ICB 5, 6. WPRT is used to treat the primary tumor (or tumor bed), parametrial tissues, and regional (pelvic) lymph nodes.
Unlike ICB, WPRT results in the irradiation of large volumes of the small bowel and rectum, commonly leading to gastrointestinal (GI) toxicity in these patients 7, 8. Acute GI symptoms typically involve varying degrees of diarrhea, cramping, and abdominal discomfort. Chronic (late) toxicity may arise months to years after WPRT. Although severe chronic toxicities (proctitis, obstruction, fistulas) are uncommon, many women treated with WPRT, nonetheless, suffer from a variety of chronic problems including intermittent diarrhea, intolerance to certain foods, and malabsorption of vitamins, lactose, and bile acids (9).
In an effort to reduce the volume of small bowel and rectum irradiated (and thus the risk of GI sequelae) in gynecology patients, we began exploring the use of intensity-modulated WPRT (IM-WPRT) in our clinic. Unlike conventional RT, intensity-modulated radiotherapy (IMRT) utilizes beams of varying intensity that conform the high dose region to the shape of the target tissues in three dimensions, thereby minimizing the dose to the surrounding organs. We 10, 11 and others 12, 13, 14, 15 have shown that IMRT planning significantly reduces the volume of both small bowel and rectum in gynecology patients undergoing WPRT. Moreover, in a series of reports 16, 17, we have noted that gynecology patients treated with IM-WPRT experience less acute GI toxicity than those treated with conventional techniques.
The question remains, however, whether IM-WPRT treatment reduces the incidence and severity of chronic GI toxicity in these patients. We began treating gynecology patients with IM-WPRT in February 2000. At present, a number of women have completed therapy and have been followed for over 1 year. The purpose of this report is to provide a preliminary analysis of chronic GI sequelae in these patients.
Section snippets
Methods and materials
Between February 2000 and August 2001, 37 women with gynecologic malignancies underwent IM-WPRT in the Department of Radiation and Cellular Oncology at the University of Chicago. One patient was excluded from our analysis due to the development of a symptomatic locoregional recurrence, leaving 36 evaluable patients for analysis of GI toxicity. The characteristics of these patients are shown in Table 1. Most (56%) had cervical cancer, predominantly Stages I–II. Whereas 9 underwent RT alone, 27
Results
Overall, 4 IM-WPRT patients (11%) developed chronic GI toxicity: 3 Grade 1 and 1 Grade 2. All four complained of diarrhea after the ingestion of certain foods, predominantly raw fruit and/or vegetables. The sole Grade 2 patient required infrequent antidiarrheal medications due to food intolerances. No IM-WPRT patient developed a Grade 3 chronic GI toxicity. Thirty-two IM-WPRT patients (89%) stated that they had no GI symptoms and were able to eat all types of food.
Fifteen WPRT patients (50%)
Discussion
The application of IMRT in gynecologic oncology patients has been receiving increasing attention in the literature 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27. By far, the majority of these reports have focused on the use of IM-WPRT 10, 11, 12, 13, 16, 17, 19, 20, 21, 23, 26, 27. In our initial comparison study (10), we found that the small bowel volume treated to the prescription dose was reduced by a factor of 2 using IM-WPRT. In addition, the volume of rectum and
References (34)
- et al.
Radiotherapy alone for medically inoperable carcinoma of the cervixStage IA and carcinoma in situ
Int J Radiat Oncol Biol Phys
(1991) - et al.
A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomyA Gynecologic Oncology Group Study
Gynecol Oncol
(1999) - et al.
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinomaMulticentre randomised trial
PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet
(2000) - et al.
The morbidity of treatment for patients with stage I endometrial cancerResults from a randomized trial
Int J Radiat Oncol Biol Phys
(2001) - et al.
Intensity modulated whole pelvic radiation therapy in patients with gynecological malignancies
Int J Radiat Oncol Biol Phys
(2000) - et al.
Intensity modulated radiation therapy in gynecologic malignancies
Med Dosim
(2002) - et al.
Comparison of IMRT with 3-D CRT for gynecologic malignancies (Abstr.)
Int J Radiat Oncol Biol Phys
(2001) - et al.
Conventional 3-D versus intensity modulated radiotherapy for the adjuvant treatment of gynecologic malignanciesA comparative study of dose–volume histograms and the potential impact on toxicities (Abstr.)
Int J Radiat Oncol Biol Phys
(2001) - et al.
Whole pelvic intensity-modulated radiotherapy (IMRT) for cervix cancer using a “butterfly” isodose planIn vivo dosimetric verification of reduced rectal dose and clinical feasibility evaluation (Abstr.)
Int J Radiat Oncol Biol Phys
(1999) - et al.
Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer
Semin Radiat Oncol
(2002)
Initial clinical experience using intensity modulated whole pelvic radiation therapy for gynecologic malignancies
Gynecol Oncol
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies
Int J Radiat Oncol Biol Phys
Does prone positioning reduce bowel dose in pelvic radiation with intensity-modulated radiation therapy (IMRT) for gynecologic cancer?(Abstr.)
Int J Radiat Oncol Biol
Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation
Int J Radiat Oncol Biol Phys
IMRT of large fieldsWhole-abdomen irradiation
Int J Radiat Oncol Biol Phys
Intensity modulated radiation therapy (IMRT) for post-hysterectomy pelvic radiationSelection of patients and planning target volume (PTV)
Int J Radiat Oncol Biol Phys
Impact of intensity modulated whole pelvic radiation therapy on acute hematologic toxicity in patients with gynecologic malignancies
Int J Radiat Oncol Biol Phys
Cited by (298)
Patient Reported Outcomes for Women Undergoing Definitive Chemoradiation for Gynecologic Cancer: A Prospective Clinical Trial
2023, Practical Radiation OncologyOverall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study
2023, International Journal of Radiation Oncology Biology PhysicsImage Guidance Volume-Modulated Arc Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin for Patients With Locally Advanced Cervical Cancer: A Single-Arm Dose Escalation Trial
2023, International Journal of Radiation Oncology Biology PhysicsRadiotherapy for endometrial cancer
2022, Cancer/RadiotherapieTrials and tribulations of bone marrow sparing radiotherapy for cervical cancer
2022, Radiotherapy and Oncology
- ☆
Supported by a grant from the Illinois Department of Public Health.